CAS 74103-07-4|Ketorolac tromethamine

Introduction：Basic information about CAS 74103-07-4|Ketorolac tromethamine, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Table of Contents

1. Names
2. Ketorolac tromethamine BiologicalActivity
3. Chemical & Physical Properties
4. Toxicological Information
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATA
ACUTE TOXICITY DATA
5. Safety Information
6. Customs
7. Articles64
8. Synonyms

Common Name	Ketorolac tromethamine
CAS Number	74103-07-4	Molecular Weight	376.404
Density	/	Boiling Point	493.2ºC at 760 mmHg
Molecular Formula	C₁₉H₂₄N₂O₆	Melting Point	160-161ºC
MSDS	ChineseUSA	Flash Point	252.1ºC
Symbol	GHS06	Signal Word	Danger

Names

Name	ketorolac tromethamine
Synonym	More Synonyms

Ketorolac tromethamine BiologicalActivity

Description	Ketorolac tromethamine salt is a non-steroidal anti-inflammatory agent, acting as a nonselective COX inhibitor, with IC50s of 20 nM for COX-1 and 120 nM for COX-2.
Related Catalog	Research Areas >>Inflammation/Immunology
Target	COX-1:20 nM (IC50) COX-2:120 nM (IC50)
In Vitro	Ketorolac is a non-steroidal anti-inflammatory agent, acting as a nonselective COX inhibitor, with IC50s of 20 nM for COX-1 and 120 nM for COX-2[1].
In Vivo	Ketorolac tromethamine (0.4%) causes nearly complete inhibition on LPS endotoxin-induced increases in FITC-dextran in the anterior chamber, and increases in aqueous PGE2 concentrations in the aqueous humor in rabbits[1].Ketorolac (30 mg/kg, i.v.) rapidly reverses hyperalgesia in rats. Ketorolac also reduces carrageenan-induced hyperalgesia and paw PG production, and causes reduction in PGE2 levels in rats[1]. Ketorolac (4 mg/kg/day, p.o.) has no detrimental effect in the volume fraction of bone trabeculae formed inside the alveolar socket in rats[2]. Ketorolac (60 μg/10 μL) reduces the histological changes such as ischemic cell death, including cytoplasmic eosinophilia with disintegration of cytoarchitecture and nuclear pyknosis in rats. Ketorolac also effectively reduces neuronal death and improves hindlimb motor function, and the long-term survival is similar to that in the control group[3].
Animal Admin	Rats[2] Treated rats receive oral doses of 1 mL aqueous solution of paracetamol (80 mg/kg/rat/day), Ketorolac (4 mg/kg/day) or etoricoxib (10 mg/kg/day) administered by gavage from the day of surgery until death, 2 weeks later. Control rats receive tap water (1 mL/day by gavage). The animals are housed under climate-controlled environment (12 h light/12 h dark, 20-24ºC) with free access to standard laboratory chow and tap water[2].
References	[1]. Waterbury LD, et al. Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133-40. [2]. Fracon RN, et al. Treatment with paracetamol, ketorolac or etoricoxib did not hinder alveolar bone healing: a histometric study in rats. J Appl Oral Sci. 2010 Dec;18(6):630-4. [3]. Hsieh YC, et al. Intrathecal ketorolac pretreatment reduced spinal cord ischemic injury in rats. Anesth Analg. 2005 Apr;100(4):1134-9.

Chemical & Physical Properties

Boiling Point	493.2ºC at 760 mmHg
Melting Point	160-161ºC
Molecular Formula	C₁₉H₂₄N₂O₆
Molecular Weight	376.404
Flash Point	252.1ºC
Exact Mass	376.163422
PSA	146.01000
LogP	0.65210
InChIKey	BWHLPLXXIDYSNW-UHFFFAOYSA-N
SMILES	NC(CO)(CO)CO.O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O
Storage condition	Hygroscopic, Refrigerator, Under Inert Atmosphere
Water Solubility	H2O: 15 mg/mL stable at least one month at −20 °C., soluble

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :: UY7759900

CAS REGISTRY NUMBER :: 74103-07-4

LAST UPDATED :: 199712

DATA ITEMS CITED :: 6

MOLECULAR FORMULA :: C15-H13-N-O3.C4-H11-N-O3

MOLECULAR WEIGHT :: 376.45

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Intramuscular

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 15 mg/kg/6D-I

TOXIC EFFECTS :: Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Nutritional and Gross Metabolic - changes in potassium Nutritional and Gross Metabolic - body temperature increase

REFERENCE :: AIMDAP Archives of Internal Medicine. (AMA, 535 N. Dearborn St., Chicago, IL 60610) V.1- 1908- Volume(issue)/page/year: 153,1000,1993

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intramuscular

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 19853 ug/kg/12D-I

TOXIC EFFECTS :: Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis)

REFERENCE :: APHRER Annals of Pharmacotherpy. (Harvey Whitney Books Co., POB 42696, Cincinnati, OH 45242) V. 26- 1992- Volume(issue)/page/year: 27,1055,1993

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intramuscular

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 857 ug/kg

TOXIC EFFECTS :: Cardiac - pulse rate increase, without fall in BP Vascular - BP lowering not characterized in autonomic section Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis)

REFERENCE :: JTCTDW Journal of Toxicology, Clinical Toxicology. (Marcel Dekker, 270 Madison Ave., New York, NY 10016) V.19- 1982- Volume(issue)/page/year: 32,305,1994

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intramuscular

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 8400 ug/kg/3D-I

TOXIC EFFECTS :: Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Nutritional and Gross Metabolic - changes in potassium

REFERENCE :: AJKDDP American Journal of Kidney Diseases. (Grune & Stratton, Inc., Journal Subscription Dept., POB 6280, Duluth, MN 55806) V.1- 1981- Volume(issue)/page/year: 24,578,1994

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intramuscular

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 1200 ug/kg

TOXIC EFFECTS :: Behavioral - hallucinations, distorted perceptions Lungs, Thorax, or Respiration - bronchiolar constriction Lungs, Thorax, or Respiration - dyspnea

REFERENCE :: SMJOAV Southern Medical Journal. (Southern Medical Assoc., POB 2446, Birmingham, AL 35205) V.1- 1908- Volume(issue)/page/year: 87,282,1994

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intramuscular

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 858 ug/kg

TOXIC EFFECTS :: Cardiac - pulse rate increase, without fall in BP Lungs, Thorax, or Respiration - dyspnea Immunological Including Allergic - anaphylaxis

REFERENCE :: APHRER Annals of Pharmacotherpy. (Harvey Whitney Books Co., POB 42696, Cincinnati, OH 45242) V. 26- 1992- Volume(issue)/page/year: 26,1237,1992

Safety Information

Symbol	GHS06
Signal Word	Danger
Hazard Statements	H301-H315-H319-H335
Precautionary Statements	P261-P301 + P310-P305 + P351 + P338
Personal Protective Equipment	Eyeshields;Faceshields;Gloves;type P2 (EN 143) respirator cartridges
Hazard Codes	T:Toxic
Risk Phrases	R25;R36/37/38
Safety Phrases	S26-S45
RIDADR	UN 2811
WGK Germany	3
RTECS	UY7759900
Packaging Group	II
Hazard Class	6.1(a)
HS Code	2942000000

Customs

HS Code	2942000000

Articles64

Topical cyclosporine a 1% for the treatment of chronic ocular surface inflammation.

Eye Contact Lens 40(5) , 283-8, (2014)

To evaluate the use of topical cyclosporine A (CsA) 1% emulsion in the treatment of chronic ocular surface inflammation (OSI).We conducted a retrospective chart review of patients with various forms o...

Ketorolac eye drops reduce inflammation and delay re-epithelization in response to corneal alkali burn in rabbits, without affecting iNOS or MMP-9.

Arq. Bras. Oftalmol. 78 , 67-72, (2015)

To assess the effects of 0.5% ketorolac tromethamine without preservatives on the expression of iNOS and MMP-9 in alkali burn ulcers.Twelve eyes of 120-day-old male rabbits were treated (TG) every 6 h...

Ketorolac tromethamine pharmacokinetics and metabolism after intravenous, intramuscular, and oral administration in humans and animals.

Pharmacotherapy 10(6 ( Pt 2)) , 33S-39S, (1990)

In humans, ketorolac is completely bioavailable and its kinetics are linear. It is absorbed rapidly (half-life for absorption 3.8 min) after oral (fasting) and intramuscular administration; food delay...

Synonyms

Ketorolac tromethamine

5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid - 2-amino-2-(hydroxymethyl)propane-1,3-diol (1:1)

2-amino-2-(hydroxymethyl)propane-1,3-diol,5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid

5-(phenylcarbonyl)-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid - 2-amino-2-(hydroxymethyl)propane-1,3-diol (1:1)

1H-Pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1)

Ketorolac tris salt

rac Ketorolac Tromethamine Salt

(±)-Ketorolac Tromethamine Salt

MFCD00887595

5-(Phenylcarbonyl)-2,3-dihydro-1H-pyrrolizin-1-carbonsäure--2-amino-2-(hydroxymethyl)propan-1,3-diol(1:1)

5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid - 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1)

1,3-Dihydroxy-2-(hydroxymethyl)propan-2-aminium 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylate

Ketorolac (tromethamine salt)

Recommended......